Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or mildly reduced ejection fraction.According to the CDC, 6.7 million U.S.

Adjusted analyses associated overestimation with nearly doubled 2-year mortality (aHR 1.98; 95% CI, 1.04-3.77). Differences in advanced-therapy receipt did not explain the mortality signal, suggesting ...

Patients with heart failure with preserved ejection fraction (HFpEF) present with non-specific symptoms, but are common in primary care. Most patients are not diagnosed with HFpEF until they develop ...

Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

Improvements in optimal medical therapy for patients with heart failure with reduced ejection fraction (HFrEF) have helped reduce the risk of sudden cardiac death (SCD)—in the modern era, though, just ...

The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for people with heart failure with ...

An experimental transcatheter shunt system that moves blood from the left atrium to the right atrium in patients with heart failure provided even greater benefit at 2 years than in the first year, ...